atp152
Vaccineexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 13, 2023 (NCT05846516)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - Tumor antigen
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05846516 | Phase 1 | Mar 13, 2023 | Amal Therapeutics, Boehringer Ingelheim, New York University, University of Texas at Houston |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amal Therapeutics | For profit | 1 | 1 | 1 | 2023 |
| Boehringer Ingelheim | For profit | 1 | 0 | 1 | 2023 |
| New York University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1